Open label evaluation of cannabidiol in dystonic movement disorders

PMID:

Citation Count:

103

H5 Index:

49

SJR:

n/a

Keywords & Tags:

Parkinson’s Disease, Dystonia, Neurological Disorders, CBD, Human Trial, Open Label Trail, anti-dystonic

Participants:

5 Patients

Dosage:

100 - 600 mg / day

Duration:

42 Days

Route:

Oral

Highlights & Conclusions:

Dose-related improvement in dystonia was observed in all patients and ranged from 20 to 50%. Side-effects of CBD were mild and included hypotension, dry mouth, psychomotor slowing, lightheadedness, and sedation. In 2 patients with coexisting Parkinsonian features, CBD at doses over 300 mg/day exacerbated the hypokinesia and resting tremor. CBD appears to have antidystonic and Parkinsonism-aggravating effects in humans.